InSightec is a private company that was founded specifically to develop MR (magnetic resonance) guided Focused Ultrasound technology.

• 1999-Insightec was founded by merging technology from GE Healthcare (then GE Medical Systems) and Israel’s Elbit Medical Imaging.

• The ExAblate 2000, a combination of Magnetic Resonance imaging and Focused Ultrasound (MRgFUS) technology, was created when members of the company's management, Jacob Vortman and Shuki Vitek combined their know-how and experience, after developing night-vision systems and the Black Anchor - the target missile used in the trials of the Arrow missile at Rafael, Israel's Armament Development Authority.

• 2002/2004-ExAblate 20000 received its European CE Mark and U.S. Food and Drug Administration approvals to use the ExAblate 2000 for the treatment of uterine fibroids, a pervasive condition that impacts up to 70% of women of childbearing age.

• 2005-GE healthcare announced its intention to internationally market and sell the ExAblate 2000.

• 2007-Insightec received FDA approval to use ExAblate 2000 with GE Healthcare’s 3 Tesla MRI System which provides women greater access to the procedure.

• 2007- InSightec Received the European CE Mark and USFDA approval for ExAblate 2000 treatment of pain caused by bone metastases.

• To date, the ExAblate 2000, is still the only technology of its kind with both FDA approved and the CE Mark (the EU safety mark).

• The ExAblate 2000 makes hysterectomy procedures obsolete and allows patients to avoid invasive and painful surgery, general anesthesia, extended hospitalization, a lengthy recovery time and multiple side effects.

• InSightec has clinical collaborations with leading hospitals and medical research institutions around the world, including: Women’s Hospital of Harvard, the Mayo Clinic, Johns Hopkins Hospital, St. Mary's Hospital of Imperial College, Germany's Charite Hospital and Japan's IseiKai Hospital.

• Insightec has launched an extensive research program to conduct clinical trials using the ExAblate 2000 technology in other applications including breast, bone, brain tumors and liver, while continuing clinical trials in uterine fibroids.

Awards:

• 2008 - The World Economic Forum selected the company as one of its Technology Pioneers for 2008.
• 2007-Red Herring magazine named InSightec to its Red Herring 100 Europe 2007 list of the top privately-held technology companies in Europe, the Middle East and Africa (EMEA)

·         2005-Imaging Solutions of the Year" by "Advanced Imaging'" Magazine.

·         2005 - Technical Innovation Award in the field of non-invasive medical devices for outstanding industry achievement by Frost & Sullivan, the international growth consultants.

·         2004 - Technology Innovation bronze award by The Wall Street Journal.

·         2004-winner of €200,000 Grand Prize of the European Information Society Technologies (IST).

• 2002 - Business Week called ExAblate 2000 “one of 25 ideas for a changing world.”